Mesenchymal stem cells injected into carotid artery to target focal brain injury home to perivascular space.

Quantitative analysis of extravasating cells revealed a strong trend towards a higher percentage of naive compared to engineered hBM-MSCs (51±13.25% and 39±10.40%, respectively) present in the perivascular space; however, the difference was not statistically significant (p=0.06) (Figure 4 B). mRNA-ITGA4 transfected hBM-MSCs are more vulnerable to phagocytosis in vivo The identity of transplanted hBM-MSCs was confirmed using anti-CD44 staining in recipient brains collected 3 days after cell transplantation (Figure 5 A).

also in 5,725 other papers